188 related articles for article (PubMed ID: 36278891)
1. Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials.
Xie K; Ren X; Hong X; Zhu S; Wang D; Ye X; Ren X
Bioengineered; 2022 Jun; 13(6):14827-14839. PubMed ID: 36278891
[TBL] [Abstract][Full Text] [Related]
2. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
4. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
[TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
6. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
Saleh RR; Nadler MB; Desnoyers A; Meti N; Fazelzad R; Amir E
Cancer Treat Rev; 2021 Nov; 100():102283. PubMed ID: 34530283
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
Yang R; Shi YY; Han XH; Liu S
Oncol Res Treat; 2021; 44(6):333-343. PubMed ID: 33975311
[TBL] [Abstract][Full Text] [Related]
8. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis.
Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G
Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
[TBL] [Abstract][Full Text] [Related]
10. Platinum chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.
Li J; Shen G; Wang M; Huo X; Zhao F; Ren D; Zhao Y; Zhao J
Clin Exp Med; 2023 Sep; 23(5):1489-1499. PubMed ID: 36152119
[TBL] [Abstract][Full Text] [Related]
12. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer.
Feng W; He Y; Xu J; Zhang H; Si Y; Xu J; Li S
Anticancer Drugs; 2022 Jan; 33(1):e52-e60. PubMed ID: 34371505
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
Liu Z; Li J; Zhao F; Ren D; Li Z; Chen Y; Huang S; Liu Z; Zhao Y; Wang M; Li H; Xu Z; Shen G; Zhao J
BMC Cancer; 2024 Apr; 24(1):440. PubMed ID: 38594636
[TBL] [Abstract][Full Text] [Related]
15. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Lu F; Hou Y; Chen Z; Jiang J; He X; Xia Y; Cao K; Chang L; Li W
Technol Cancer Res Treat; 2021; 20():15330338211016369. PubMed ID: 33977814
[TBL] [Abstract][Full Text] [Related]
17. Neo-adjuvant therapy for triple-negative breast cancer: Insights from a network meta-analysis.
Miyashita H; Satoi S; Cruz C; Malamud SC
Breast J; 2020 Sep; 26(9):1717-1728. PubMed ID: 32657479
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
Xiu M; Zhang P; Wang X; Fan Y; Li Q; Li Q; Wang J; Dong L; Luo Y; Yuan P; Ma F; Xu B
Int J Cancer; 2022 Aug; 151(4):578-589. PubMed ID: 35403702
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.
Jia X; Wang K; Xu L; Li N; Zhao Z; Li M
Breast; 2022 Dec; 66():31-39. PubMed ID: 36096071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
